The purpsoe of this study is to determine the relapse-free survival (RFS) benefit from the addition of a maintenance olaparib following completion of chemotherapy in patients with resected pancreatic carcinoma and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2.

Eligibility:

• Patient must be ≥18 years of age on day of consent.
• Patient must have an ECOG Performance Status of 0-2.
• Patient must have a diagnosis of pancreatic cancer and have successfully undergone a curative intent surgical resection and must have no evidence of recurrent disease as determined by the investigator.
• NOTE: This includes patients with adenocarcinoma, acinarcarcinoma, squamous cell carcinoma adenosquamous and variants thereof. Patients with neuroendocrine tumors are excluded from enrolling.
• Additonal criteria must be met based on determination by Investigator and study requirements

You may be eligible for this study if you meet the following criteria:

• Conditions: pancreatic cancer
• Age: 18 years - 100 years
• Gender: All